Key result
The article reviews updated guidelines for atherosclerosis and dyslipidemias, highlighting extreme risk categories, revised LDL-C targets, and the expanded role of PCSK9 inhibitors.
Why the study?
New approaches and updates in the pathogenesis, risk factors, diagnosis, and treatment of atherosclerosis and dyslipidemias were needed to reflect recent guideline revisions and clinical practice changes.
Answers are grounded in this paper and cite their sources.
This review highlights key updates in the management of dyslipidemia and atherosclerosis, emphasizing stricter LDL-C targets and the role of PCSK9 inhibitors for extreme-risk patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Сергиенко et al. (2021) conducted a review in Atherosclerosis and dyslipidemias. The article reviews updated guidelines for atherosclerosis and dyslipidemias, highlighting extreme risk categories, revised LDL-C targets, and the expanded role of PCSK9 inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: